Premium
INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
Author(s) -
Herrera A.F.,
Moskowitz A.J.,
Bartlett N.L.,
Vose J.M.,
Ramchandren R.,
Feldman T.A.,
Lacasce A.S.,
Ansell S.M.,
Moskowitz C.H.,
Fenton K.,
Ogden C.,
Taft D.,
Zhang Q.,
Kato K.,
Campbell M.,
Advani R.H.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_73
Subject(s) - medicine , brentuximab vedotin , nivolumab , refractory (planetary science) , adverse effect , oncology , lymphoma , anaplastic large cell lymphoma , cd30 , immunotherapy , cancer , physics , astrobiology